Last Updated: September 16, 2026
The choice between carve-in and carve-out decides every claim field that follows. Carve-in bills Medicaid for 340B-purchased drugs at the lower reimbursement; carve-out buys outside 340B and bills standard rates.
| Factor | Carve-In | Carve-Out |
|---|---|---|
| Drug purchase | 340B ceiling price | Non-340B (WAC or contract) |
| Medicaid billing | 340B ceiling price plus dispensing fee | Standard Medicaid rates |
| Exclusion File | Medicaid ID must appear | Medicaid ID must not appear |
| Duplicate discount risk | Managed through claim fields | Avoided by design |
| Best for | High Medicaid volume, strong billing controls | Thin margins, complex plan mix |
Florida's Agency for Health Care Administration publishes the state's 340B billing instructions, and those instructions govern how fee-for-service pharmacy claims must be submitted. Covered entities should treat AHCA 340B billing guidance as the controlling source and reconcile internal billing rules against it each year.
Three claim fields decide whether a Florida FFS pharmacy claim pays correctly:
For FFS claims, ingredient cost is capped at the 340B ceiling price, with Florida's dispensing fee added on top. Billing above ceiling price invites recoupment; billing below creates reconciliation problems later.
The Medicaid Exclusion File is HRSA's public record of which covered entities bill Medicaid for 340B drugs. If an entity's Medicaid ID is not on that file, it cannot bill carve-in, full stop.
Duplicate discount prevention is the reason carve-in billing rules exist. A duplicate discount happens when a manufacturer pays a 340B discount and Medicaid also receives a rebate on the same drug.
Prevention depends on three controls working together:
Managed care encounters follow a different path than FFS. Each Florida Medicaid managed care organization publishes its own companion guide, and where a plan diverges from the state spec, the companion guide wins.
Plan-level differences show up in five places, and each one needs to be confirmed in writing before go-live:
In our experience, the fastest way to surface plan-level divergence is a small live test before volume goes through:
Encounter data feeds AHCA's Medicaid rebate process. If a 340B encounter is submitted without the correct SCC combination, the state may invoice the manufacturer for a rebate on a drug that already received a 340B discount. That is a duplicate discount, and the entity carries the repayment risk, not the plan or the pharmacy.
Managed care carve-in is a per-plan configuration problem, not a state-spec problem. Test each plan before go-live, document the accepted SCC combination, and reconcile encounter reports against dispensing data monthly.
Contract pharmacy arrangements add complexity to carve-in billing because the entity is responsible for what the pharmacy submits, even though the pharmacy controls the claim. Most carve-in margin problems show up in the pharmacy statement long before an audit.
In our experience, the most common contract pharmacy mistake is reading the monthly statement on a cash basis only. Cash-basis "cumulative over/under" ledgers can show the clinic owing the pharmacy while accrual shows the pharmacy holding clinic margin in trailing insurer A/R, typically ~30% collected in-month and ~70% the next month, so the cash ledger lags reality by a full cycle.
The carve-in vs carve-out decision is not made at the program level. It is made at the drug-class level, using net-per-claim after dispensing fees and after the pharmacy's share.
Monthly reconciliation is the control that makes carve-in defensible: the entity's dispensing data matched against the pharmacy's reported claims, documented.
When a covered entity changes contract pharmacies, the sequencing matters more than the contract terms. The order we use in programs we run:
Audit readiness is not a project you start when HRSA sends a notice. It is records maintained continuously so the response is assembly, not investigation.
The records that matter most:
Carve-in billing in Florida Medicaid rewards entities that treat claim fields, the Medicaid Exclusion File, and contract pharmacy reporting as one connected system rather than three separate tasks. The entities that pass audits reconcile monthly, not annually.
Your entity's Medicaid provider ID has to appear on the HRSA Medicaid Exclusion File for the period you are billing. HRSA builds that file from what you report during recertification and any time you change your Medicaid billing status. If the ID is missing, or the file shows you as carved out while you bill FFS claims with 340B pricing, you have a duplicate discount exposure. Reconcile the file against your state Medicaid enrollment every quarter, not once a year. In our experience, the mismatch usually traces to a new location or a re-enrollment that nobody told the 340B program manager about.
AHCA's 340B instructions govern this. FFS pharmacy claims carry Basis of Cost Determination 08 and Submission Clarification Code 20, and the ingredient cost is capped at the 340B ceiling price plus Florida's dispensing fee. The ceiling price is drug-specific, so pull it from your 340B TPA or wholesaler pricing file rather than estimating. Bill the claim through the same pharmacy or medical channel you normally use, but confirm the 08 and 20 fields actually transmit; some switches drop them silently. Test one claim and read the remittance before you push volume through a new configuration.
On managed care encounter claims, SCC 20 signals 340B pricing and SCC 9 signals that the claim is a Medicaid encounter, and plans apply them per their own companion spec. Some plans want both on the same claim; others want 20 on the pharmacy claim and 9 on the encounter record. Send a test claim to each plan, get the confirmation in writing from your provider relations contact, and keep that document in your audit file. When a plan changes its spec, it rarely announces it, so re-verify at least annually.
Duplicate discount prevention rests on three controls. First, keep the Medicaid Exclusion File accurate so HRSA and manufacturers know which claims carry 340B pricing. Second, make sure every carved-in Medicaid claim transmits the 340B indicators so the manufacturer does not also pay a Medicaid rebate on it. Third, reconcile your TPA's claim-level data against your Medicaid remittance monthly, looking for claims that show 340B pricing without the indicators or the reverse. In programs we run, the monthly reconciliation catches more exposure than any annual audit prep.
Carve-in makes sense when your Medicaid volume is meaningful, your team can execute the claim fields cleanly, and the 340B margin on those claims exceeds the administrative cost of billing them correctly. Carve-out is usually the better call when Medicaid is a small share of your pharmacy volume, when your plans' encounter specs keep changing, or when you cannot staff the reconciliation. There is no universal right answer, and the decision can differ by drug class. Model it on your own claims, not on a rule of thumb.
Bring us your patient acquisition, 340B program, or compliance bottleneck. We will show you what a 30-day launch looks like for your clinic — in English or Spanish, month to month, no long contract.
